Detalhe - 0

Produções afetadas
Endereço - INCT Sangue Hemoctr
1)
PT
J
TI
Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the
phase 3 B-LONG study
DT
Meeting Abstract
C1
[Powell, J.] Univ Calif Davis, Davis, CA 95616 USA.
[Apte, S.] Sahyadri Hosp, Mahara, India.
[Chambost, H.] Ctr Regional Traitement Hemophiles, Marseille, France.
[Hermans, C.] Clin Univ St Luc, B-1200 Brussels, Belgium.
[Jackson, S.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada.
[Josephson, N.] Puget Sound Blood Ctr, Seattle, WA 98104 USA.
[Mahlangu, J.] Haemophilia Comprehens Care Ctr, Johannesburg, South Africa.
[Ozelo, C. M.] Univ Estadual Campinas, INCT Sangue Hemoctr, Campinas, SP, Brazil.
[Peerlinck, K.] Univ Hosp Gasthuisberg, Apotheek, Louvain, Belgium.
[Allen, G.] Biogen Idec Inc, Weston, MA USA.
PY
2013
ER
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------2)
PT
J
TI
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in
the phase 3 B-LONG study
DE
clinical trial; phase 3; factor IX; haemophilia B; pharmacokinetics; surgery;
DT
Article
ID
SURGERY; PHARMACOKINETICS
C1
[Powell, Jerry S.] Univ Calif Davis, Sacramento, CA 95817 USA.
[Apte, Shashikant] Sahyadri Hosp, Dept Haematol, Mahara, India.
[Chambost, Herve] Aix Marseille Univ, Hop Enfants La Timone, APHM, CTH,Serv Hematol Pediat, Marseille, France.
[Hermans, Cedric] Clin Univ St Luc, B-1200 Brussels, Belgium.
[Jackson, Shannon] St Pauls Hosp, Hemophilia Program BC Adult Div, Vancouver, BC V6Z 1Y6, Canada.
[Josephson, Neil C.] Puget Sound Blood Ctr, Seattle, WA 98104 USA.
[Mahlangu, Johnny N.] Univ Witwatersrand, Haemophilia Comprehens Care Ctr, NHLS, Johannesburg, South Africa.
[Mahlangu, Johnny N.] Johannesburg Hosp, Johannesburg, South Africa.
[Ozelo, Margareth C.] Univ Estadual Campinas, INCT Sangue Hemoctr, Campinas, SP, Brazil.
[Peerlinck, Kathelijne] Univ Hosp Gasthuisberg, Leuven, Belgium.
[Pasi, John] Barts & London Comprehens Care Ctr, London, England.
[Perry, David] Addenbrookes Hosp, Cambridge, England.
[Ragni, Margaret V.] Univ Pittsburgh, Pittsburgh, PA USA.
[Ragni, Margaret V.] Hemophilia Ctr Western Penn, Pittsburgh, PA USA.
[Wang, Xuefeng] Shanghai Jiao Tong Univ, Sch Med, Dept Haematol, Ruijin Hosp, Shanghai 200030, Peoples R China.
[Jiang, Haiyan; Li, Shuanglian; Cristiano, Lynda M.; Innes, Alison; Nugent, Karen; Brennan, Aoife; Luk, Alvin; Allen, Geoffrey;
Pierce, Glenn F.; Robinson, Brian] Biogen Idec Inc, Cambridge, MA 02142 USA.
PY
2015
ER
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------3)
PT
J
TI
Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion
Protein ( rFIXFc) in the B-LONG and Kids B-LONG Studies
30/09/2016
UNICAMP / Centro de Computação
Página 1 / 2
Produções afetadas
Endereço - INCT Sangue Hemoctr
DT
Meeting Abstract
C1
[Kulkarni, Roshni] Michigan State Univ, Dept Pediat & Human Dev, E Lansing, MI 48824 USA.
[Shapiro, Amy D.] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA.
[Windyga, Jerzy] Inst Haematol & Transfus Med, Dept Disorders Haemostasis & Internal Med, Warsaw, Poland.
[Ragni, Margaret V.] Univ Pittsburgh, Pittsburgh, PA USA.
[Ragni, Margaret V.] Hemophilia Ctr Western PA, Pittsburgh, PA USA.
[Pasi, K. John] Barts & London Comprehens Care Ctr, London, England.
[Ozelo, Margareth Castro] Univ Estadual Campinas, INCT Sangue Hemoctr, Campinas, Brazil.
[Tsao, Elisa; Mei, Baisong] Biogen, Cambridge, MA USA.
PY
2015
ER
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------4)
PT
J
TI
Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption
and lower bleeding rates
DE
administration and dosage; factor IX; haemophilia B; pharmacokinetics; recombinant fusion protein;
DT
Article
ID
PREVIOUSLY TREATED PATIENTS; SEVERE HEMOPHILIA-B; PROLONGED ACTIVITY; MODERATELY SEVERE; EFFICACY;
SAFETY; PHARMACOKINETICS; GUIDELINES; DISEASE; BURDEN
C1
[Powell, Jerry] Univ Calif Davis, Sacramento, CA 95817 USA.
[Shapiro, Amy] Indiana Hemophilia & Thrombosis Ctr, Dept Hematol, Indianapolis, IN USA.
[Ragni, Margaret] Univ Pittsburgh, Pittsburgh, PA USA.
[Ragni, Margaret] Hemophilia Ctr Western Penn, Pittsburgh, PA USA.
[Negrier, Claude] Hop Edouard Herriot, Lyon, France.
[Windyga, Jerzy] Inst Haematol & Transfus Med, Dept Disorders Haemostasis & Internal Med, Warsaw, Poland.
[Ozelo, Margareth] Univ Estadual Campinas, INCT Sangue Hemoctr, Campinas, SP, Brazil.
[Pasi, John] Barts & London Queen Marys Sch Med & Dent, London, England.
[Baker, Ross] Murdoch Univ, Western Australian Ctr Thrombosis & Haemostasis, Murdoch, WA 6150, Australia.
[Potts, James; Li, Shuanglian; Mei, Baisong; Pierce, Glenn F.; Robinson, Brian] Biogen Idec Inc, Cambridge, MA 02142 USA.
PY
2015
ER
30/09/2016
UNICAMP / Centro de Computação
Página 2 / 2